68,809 Shares in BioLife Solutions, Inc. $BLFS Bought by Squarepoint Ops LLC

Squarepoint Ops LLC acquired a new stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 68,809 shares of the medical equipment provider’s stock, valued at approximately $1,482,000. Squarepoint Ops LLC owned about 0.14% of BioLife Solutions as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Thrivent Financial for Lutherans boosted its stake in shares of BioLife Solutions by 2.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 27,278 shares of the medical equipment provider’s stock worth $588,000 after purchasing an additional 702 shares during the period. Public Sector Pension Investment Board lifted its stake in BioLife Solutions by 10.3% in the second quarter. Public Sector Pension Investment Board now owns 126,465 shares of the medical equipment provider’s stock worth $2,724,000 after purchasing an additional 11,769 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in BioLife Solutions by 9.8% in the second quarter. CANADA LIFE ASSURANCE Co now owns 34,692 shares of the medical equipment provider’s stock worth $747,000 after purchasing an additional 3,110 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of BioLife Solutions by 547.9% during the second quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock valued at $154,000 after buying an additional 6,032 shares during the period. Finally, Man Group plc purchased a new position in shares of BioLife Solutions during the second quarter valued at approximately $234,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BLFS. Zacks Research downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research note on Monday, November 24th. Wall Street Zen downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $31.00.

Insider Activity

In related news, Director Joydeep Goswami sold 1,666 shares of BioLife Solutions stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $28.99, for a total value of $48,297.34. Following the completion of the sale, the director directly owned 44,986 shares in the company, valued at $1,304,144.14. The trade was a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Greef Roderick De sold 37,795 shares of the stock in a transaction dated Wednesday, October 22nd. The stock was sold at an average price of $27.30, for a total transaction of $1,031,803.50. Following the transaction, the chief executive officer owned 489,998 shares in the company, valued at approximately $13,376,945.40. The trade was a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 937,664 shares of company stock valued at $26,311,309. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Down 1.1%

Shares of NASDAQ BLFS opened at $25.07 on Friday. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62. The firm has a market cap of $1.21 billion, a PE ratio of -358.09 and a beta of 1.93. The business has a fifty day simple moving average of $26.26 and a two-hundred day simple moving average of $24.55.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.